Please Enable Images To See This
Guilty Beyond a Reasonable Doubt?
By Ben Morris and Drew McConnell, editors, DailyWealth Trader
Wednesday, January 3, 2018
You buy a stock for the long haul...

It's a great business. It trades at a great price. And you know its upside potential is huge.

For one reason or another, investors don't see the stock for what it is – a fantastic value.

So you take a medium- to large-sized position. And what do you know? The stock starts to rise.

You're right... And you're making money.

Then, doubt sets in...

You turn on the TV and Joe Analyst from Big Bank X rattles off three reasons why your stock is doomed. You turn on your computer and learn that a senior analyst from another big firm just downgraded the stock... and shares drop 5%.

"Maybe they're right," you think. "Maybe I should get out now, while I'm still up on the position."

That's dangerous thinking. You see, these types of positions are your best shots at supercharging your portfolio...

----------Recommended Links---------
Before this market doubles again
There's ONE THING you need to do: Join Dr. Richard Smith this Thursday at 8 p.m. Eastern time for an exclusive rundown of Stansberry Research's HIGHEST UPSIDE STOCKS to start 2018. You'll discover when to buy, when to sell, and how much of each to own. Click here for details and to RSVP!
This Is the Story of Your Enslavement…
You have nothing saved. You owe on your house, car, and credit card. But this was no accident. 40,000 people per day are now learning about the biggest scam EVER perpetrated against the American people – and what you can do about it. Click here for details.
---------------------------------

As our colleague Steve Sjuggerud has pointed out...

What distinguishes a great track record from an ordinary one? It's typically one thing: a couple of big winners...

If your track record includes a lot of ordinary returns and a couple of big winners, then chances are you're doing well with your investments. But if you have a lot of ordinary returns and NO big winners, then chances are you're underperforming the market.

You can't underestimate the power of big winners. You can't sell early.

So how do you prevent yourself from selling early – before your stop loss is triggered – when it seems like the reasons to abandon ship are building?

Look at the facts... And ask yourself, "Is the company guilty beyond a reasonable doubt?" Has good turned bad? Have the reasons you bought the stock in the first place reversed? Has something dramatically and permanently changed for the worse?

If not, you're likely letting emotions get the better of you.

Today, we'll look at this idea in practice. We'll review our biggest winner in DailyWealth Trader (DWT) last year...

We recommended buying shares of sparking-water and soft-drink producer National Beverage (FIZZ) on February 3. The company was growing rapidly. Its flagship brand LaCroix was flying off supermarket shelves, and its CEO owned a huge 74% stake in the company.

We said the stock had at least 50% upside potential... And we passed the 50% mark in less than two months. Not long after, the naysayers started to speak up...

On April 21, Credit Suisse downgraded the stock from an "outperform" rating to a "neutral" rating. The financial-services company's analyst stated that National Beverage was overvalued. Shares fell 5.3% that day.

On May 4, the Maxim Group issued a "sell" rating on the stock and gave it a $33 price target. It mentioned a lack of transparency and corporate governance issues. Shares fell 8.2% that day.

On July 21, Credit Suisse downgraded the stock again to a "sell" rating. It gave the stock an $82 price target. This time, the company's analyst said National Beverage's shares had come too far, too fast. Shares fell 4.3% that day.

Each time, it was tempting to think that the trouble had started for National Beverage shares. We were already up a lot in a short period of time... And smart people were saying the stock should fall.

But was National Beverage "guilty beyond a reasonable doubt"? Not by a long shot...

We checked in on the company in August to see if the naysayers were right. As it turned out, the business was doing well. Over the prior 12 months, sales and profits had jumped about 17% and 75%, respectively. Plus, it had a big 13% profit margin. So we continued holding with our 20% trailing stop.

As you can see in the chart below, shares blew past our initial 50% target. We finally stopped out of the position in October – for a 91% gain in eight months...


If we had sold National Beverage early, we could have missed the last 41% in gains.

The lesson from our biggest winner of 2017 is clear. You can hear the critics out. But don't sell based on opinions. Focus on how the business is performing.

If the stock hasn't triggered your stop loss, ask yourself, "Is the company guilty beyond a reasonable doubt?" If it's not, your best bet is to hold on.

Let your winners ride... And continue to protect yourself with trailing stops.

Good trading,

Ben Morris and Drew McConnell

Editor's note: Tomorrow night, we'll hear from expert Dr. Richard Smith on how to "unlock" your investments for the biggest potential gains. During this special event, he'll walk you through how to beat the S&P 500 by more than 300%... And he'll explain how his simple system can boost your profits during the final "Melt Up" stage of this bull market. Click here to reserve your free spot.
Further Reading:

"If you sell a stock every time you hit a certain threshold, you're limiting your gains," Dr. Richard Smith writes. To let your winners ride, you need to change your thinking... And one investing tool makes it easy. Read more here.
 
In this essay, Ben explains why selling your stocks too early is a losing behavior over time. A better way to plan your trades can keep you from throwing away hundreds, thousands, or even tens of thousands of dollars... Learn more here.
  Print


A POWERHOUSE IN HEALTH CARE

Today, we look at a company that benefits from higher demand in health care...
 
Longtime readers know our colleague Dave Eifrig believes the aging Baby Boomer generation will drive big gains in health care stocks... As the Boomers get older, they'll need to spend more money on medicine, testing, and visits to the doctor. Today, we're highlighting one of the winners of this trend...
 
Abbott Laboratories (ABT) is a leader in diagnostics, medical devices, nutrition, and generic pharmaceuticals. Its testing and diagnostic instruments are used worldwide in hospitals, labs, and doctor's offices. The company's third-quarter sales grew 5.6% year over year to $6.8 billion. And moreover, Abbott has a history of passing its success on to its shareholders... It has paid a dividend since 1924, and has increased it for the past 46 consecutive years.
 
As you can see in the chart below, shares have climbed about 50% over the past year. They're now sitting at a new all-time high. Abbott has what Dave has called "one of the world's greatest tailwinds" at its back – an aging population. And its share price will likely soar higher...
 

The crown jewel of digital journalism...
 
Newspaper companies will either adapt or die in today's digital world. And Porter Stansberry believes one company is making the right moves for the long run...
 

Are You a
New Subscriber?

If you have recently subscribed to a Stansberry Research publication and are unsure about why you are receiving the DailyWealth (or any of our other free e-letters), click here for a full explanation...
 

Advertisement

Recently, Steve Sjuggerud extended his stock market "Melt Up" forecast to 2019. For the full story on how stocks could surge higher than you imagine in the weeks ahead, click here
 
recent articles

Here's Why Long-Term Interest Rates Will Rise in 2018
By Brett Eversole
Tuesday, January 2, 2018
 
Exciting news... Economists have come out with their predictions for interest rates this year. Is this the year the economists will finally be right?
 
Tax 'Reform' May Kill These Companies Even Faster
By Justin Brill
Saturday, December 30, 2017
 
Just before Christmas, Congress passed the most significant changes to the U.S. tax code in more than 30 years...
 
You Don't Need to Predict a Market Crash... Here's Why
By Dan Ferris
Friday, December 29, 2017
 
I've only done it three times in my career. But all three times, it worked out well...
 
How to Invest for 'Fear, Uncertainty, and Doubt' Today
By Dan Ferris
Thursday, December 28, 2017
 
You need to understand what a mania looks and feels like to survive it...
 
The 'Golden Age of Value Investing' Is Coming
By Dan Ferris
Wednesday, December 27, 2017
 
The tide may be turning even sooner than I'd hoped...
 


Home | About Us | Resources | Archive | Free Reports | Privacy Policy
To unsubscribe from DailyWealth and any associated external offers, click here.

Copyright 2018 Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC., 1125 N Charles St, Baltimore, MD 21201

LEGAL DISCLAIMER: This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies) employees and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday – Friday between 9:00 AM and 5:00 PM Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles St, Baltimore, MD 21201, USA.

If you wish to contact us, please do not reply to this message but instead go to info@stansberrycustomerservice.com. Replies to this message will not be read or responded to. The law prohibits us from giving individual and personal investment advice. We are unable to respond to emails and phone calls requesting that type of information.